With the founding of Quell Therapeutics via a £35m series A financing, Syncona Ltd has created its tenth biotech start-up since its own foundation in 2012 and the investment group says other novel corporate launches can still be expected.
Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies
UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.
